Advances & Controversies in Malignant Hematology & Oncology: Hematology Expert Insights 2

Advances & Controversies in Malignant Hematology & Oncology is a one-day comprehensive meeting that presents the latest data and cutting-edge updates in the rapidly evolving fields of malignant hematology and oncology. Advances & Controversies is unique in that it addresses questions and controversies emerging from the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and other major disease-specific conferences. Faculty from Advances & Controversies were interviewed and asked to engage in a commentary style recording so that individuals who could not participate in the live conference can still benefit from these teachings/learnings. This program compiles those interviews in a viewer-friendly webcast presentation with a focus on malignant hematology.

Program topics include:
Acute Leukemias & Chronic Myelogenous Leukemia
Updates in Chronic Lymphocytic Leukemia
Hodgkin Lymphoma & Indolent Non-Hodgkin Lymphomas
Aggressive Non-Hodgkin Lymphomas
Myeloproliferative Neoplasms
Multiple Myeloma & the Evolving Role of Transplant

This activity is intended to meet the educational needs of healthcare providers involved in the care of oncology patients, including medical and surgical oncologists, hematologists, radiation oncologists and diagnostic radiologists, pathologists, oncology fellows and resident trainees, advanced care practitioners, physician assistants, nurses, naturopathic physicians and pharmacists.

Upon participating in this event, individuals will be able to:
• Discuss new data emerging from ASH, ASCO and major disease-specific conferences and implications on the current standards of care*
• Describe how genetic and cellular abnormalities influence disease severity and therapy selection
• Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
• Review how to initiate and individualize therapy
• Utilize current standards of care for patients with cancer

Pharmacist Learning Objectives: Upon participating in this event, pharmacists will be able to:
• Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
• Review how to initiate and individualize therapy

*This educational program is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.